» Articles » PMID: 32173556

APOE Genotype-dependent Pharmacogenetic Responses to Rapamycin for Preventing Alzheimer's Disease

Abstract

The ε4 allele of Apolipoprotein (APOE4) is the strongest genetic risk factor for Alzheimer's disease (AD), the most common form of dementia. Cognitively normal APOE4 carriers have developed amyloid beta (Aβ) plaques and cerebrovascular, metabolic and structural deficits decades before showing the cognitive impairment. Interventions that can inhibit Aβ retention and restore the brain functions to normal would be critical to prevent AD for the asymptomatic APOE4 carriers. A major goal of the study was to identify the potential usefulness of rapamycin (Rapa), a pharmacological intervention for extending longevity, for preventing AD in the mice that express human APOE4 gene and overexpress Aβ (the E4FAD mice). Another goal of the study was to identify the potential pharmacogenetic differences in response to rapamycin between the E4FAD and E3FAD mice, the mice with human APOE ε3 allele. We used multi-modal MRI to measure in vivo cerebral blood flow (CBF), neurotransmitter levels, white matter integrity, water content, cerebrovascular reactivity (CVR) and somatosensory response; used behavioral assessments to determine cognitive function; used biochemistry assays to determine Aβ retention and blood-brain barrier (BBB) functions; and used metabolomics to identify brain metabolic changes. We found that in the E4FAD mice, rapamycin normalized bodyweight, restored CBF (especially in female), BBB activity for Aβ transport, neurotransmitter levels, neuronal integrity and free fatty acid level, and reduced Aβ retention, which were not observe in the E3FAD-Rapa mice. In contrast, E3FAD-Rapa mice had lower CVR responses, lower anxiety and reduced glycolysis in the brain, which were not seen in the E4FAD-Rapa mice. Further, rapamycin appeared to normalize lipid-associated metabolism in the E4FAD mice, while slowed overall glucose-associated metabolism in the E3FAD mice. Finally, rapamycin enhanced overall water content, water diffusion in white matter, and spatial memory in both E3FAD and E4FAD mice, but did not impact the somatosensory responses under hindpaw stimulation. Our findings indicated that rapamycin was able to restore brain functions and reduce AD risk for young, asymptomatic E4FAD mice, and there were pharmacogenetic differences between the E3FAD and E4FAD mice. As the multi-modal MRI methods used in the study are readily to be used in humans and rapamycin is FDA-approved, our results may pave a way for future clinical testing of the pharmacogenetic responses in humans with different APOE alleles, and potentially using rapamycin to prevent AD for asymptomatic APOE4 carriers.

Citing Articles

Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.

Nehra G, Maloney B, Smith R, Chumboatong W, Abner E, Nelson P Fluids Barriers CNS. 2025; 22(1):4.

PMID: 39789614 PMC: 11720585. DOI: 10.1186/s12987-024-00615-8.


Machine Learning-Driven Prediction of Brain Age for Alzheimer's Risk: APOE4 Genotype and Gender Effects.

Woods C, Xing X, Khanal S, Lin A Bioengineering (Basel). 2024; 11(9).

PMID: 39329685 PMC: 11429338. DOI: 10.3390/bioengineering11090943.


Effect of Apolipoprotein E isoforms on the Abundance and Function of P-glycoprotein in Human Brain Microvascular Endothelial Cells.

Kreutzer E, Short J, Nicolazzo J Pharm Res. 2024; 41(7):1427-1441.

PMID: 38937373 PMC: 11263236. DOI: 10.1007/s11095-024-03731-0.


mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer's disease in an APOE genotype-dependent manner.

Sanganahalli B, Mihailovic J, Vekaria H, Coman D, Yackzan A, Flemister A J Cereb Blood Flow Metab. 2024; 44(10):1745-1758.

PMID: 38879800 PMC: 11494852. DOI: 10.1177/0271678X241261942.


Pharmacological mTOR inhibitors in ameliorating Alzheimer's disease: current review and perspectives.

Xie P, Zheng M, Han R, Chen W, Mao J Front Pharmacol. 2024; 15:1366061.

PMID: 38873415 PMC: 11169825. DOI: 10.3389/fphar.2024.1366061.


References
1.
Perluigi M, Di Domenico F, Butterfield D . mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis. 2015; 84:39-49. DOI: 10.1016/j.nbd.2015.03.014. View

2.
Lin A, Jahrling J, Zhang W, DeRosa N, Bakshi V, Romero P . Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease. J Cereb Blood Flow Metab. 2016; 37(1):217-226. PMC: 5167110. DOI: 10.1177/0271678X15621575. View

3.
Clark K, Nuechterlein K, Asarnow R, Hamilton L, Phillips O, Hageman N . Mean diffusivity and fractional anisotropy as indicators of disease and genetic liability to schizophrenia. J Psychiatr Res. 2011; 45(7):980-8. PMC: 3109158. DOI: 10.1016/j.jpsychires.2011.01.006. View

4.
Caron A, Richard D, Laplante M . The Roles of mTOR Complexes in Lipid Metabolism. Annu Rev Nutr. 2015; 35:321-48. DOI: 10.1146/annurev-nutr-071714-034355. View

5.
Janocko N, Brodersen K, Soto-Ortolaza A, Ross O, Liesinger A, Duara R . Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol. 2012; 124(5):681-92. PMC: 3483034. DOI: 10.1007/s00401-012-1044-y. View